HeraMED Advances Digital Maternity Care with Successful Lee Health Pilot
HeraMED Limited (ASX: HMD) has successfully completed Phase 1 of its Digital Pregnancy Journey pilot with Lee Health, a leading non-profit healthcare provider in Southwest Florida. The six-month evaluation assessed the HeraCARE platform within a hybrid maternity care model that combines virtual consultations, remote patient monitoring, fetal doppler technology and blood pressure tracking. Results demonstrated strong patient engagement, with 92% virtual adoption, a 100% recommendation rate and high satisfaction scores, highlighting the platform’s ability to support quality prenatal care while reducing dependence on in-person appointments.
The pilot also showed meaningful operational benefits. The digital care pathway reduced the traditional prenatal schedule from around 15 in-person visits to an 11-visit hybrid model, potentially freeing three to five appointment slots per pregnancy and creating approximately 32 additional clinic appointments. Patients benefited from lower travel requirements, reduced costs and greater convenience. Encouraged by these outcomes, HeraMED and Lee Health are progressing towards final approval for Phase 2, which could support a broader rollout of the digital maternity care program across the healthcare network.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
HeraMED Advances Digital Maternity Care with Successful Lee Health Pilot
HeraMED Limited (ASX: HMD) has successfully completed Phase 1 of its Digital Pregnancy Journey pilot with Lee Health, a leading non-profit healthcare provider in Southwest Florida. The six-month evaluation assessed the HeraCARE platform within a hybrid maternity care model that combines virtual consultations, remote patient monitoring, fetal doppler technology and blood pressure tracking. Results demonstrated strong patient engagement, with 92% virtual adoption, a 100% recommendation rate and high satisfaction scores, highlighting the platform’s ability to support quality prenatal care while reducing dependence on in-person appointments.
The pilot also showed meaningful operational benefits. The digital care pathway reduced the traditional prenatal schedule from around 15 in-person visits to an 11-visit hybrid model, potentially freeing three to five appointment slots per pregnancy and creating approximately 32 additional clinic appointments. Patients benefited from lower travel requirements, reduced costs and greater convenience. Encouraged by these outcomes, HeraMED and Lee Health are progressing towards final approval for Phase 2, which could support a broader rollout of the digital maternity care program across the healthcare network.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au